ClinicaliQ Trial Snapshot
- A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors — Recruiting • Phase I • Oncology • NCT07277270.
- What is being tested: GSK5764227, a novel targeted toxin delivery agent designed to selectively kill cancer cells, is being evaluated in combination with standard-of-care treatments or other agents in patients with advanced solid tumors.
- Patient eligibility overview: The trial enrolls adults with advanced solid tumors who have progressed on or are unsuitable for standard treatments; specific eligibility criteria vary by cohort but generally require adequate organ function and performance status.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it triggers any immune responses, and assess whether it can shrink or control cancer.
Eligibility Snapshot
- : * Has an ECOG performance status of 0 or 1, with no deterioration in the 2 weeks before first dose. * Has adequate organ function. * Has histologically confirmed unresectable adenocarcinoma or unresectable metastatic adenocarcinoma of the colon or rectum. (Cohort A) * Histologically or cytologically confirmed adenocarcinoma of the prostate (Cohort B)
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.